BACKGROUND: The major allergen of the dust mite Lepidoglyphus destructor, @entity1243 d 2, has been produced as a recombinant allergen ( @entity10672 d 2) with IgE reactivity both in vivo and in vitro. A modified form of @entity10672 d 2 ( @entity10672 d 2.6 @entity2569 ) obtained by site-directed mutagenesis has been shown to have a reduced IgE reactivity in vitro. In this study we have compared the ability of @entity10672 d 2 and @entity10672 d 2.6Cys to elicit positive skin prick tests and cellular responses among L. destructor-sensitized subjects. METHODS: Seventeen subjects were skin prick-tested with @entity10672 d 2, @entity10672 d 2.6 @entity2569 , @entity112 and negative controls and 17-20 h later skin biopsy specimens were taken from the skin prick-tested sites. The biopsy specimens were stained immunohistochemically for EG2+, CD3+, @entity4896 +, mast cell tryptase+, and IgE+ cells. @entity1358 were judged in @entity1710 and @entity1711 staining. Total IgE and allergen-specific IgE were determined by CAP-RAST. RESULTS: Compared to @entity10672 d 2, @entity10672 d 2.6 @entity2569 induced significantly smaller and fewer skin prick test reactions (p < 0.001) and dermal cell infiltrates (p < 0.05). Further, @entity10672 d 2.6 @entity2569 induced fewer EG2+ cells (p < 0.001) but more tryptase+ cells (p < 0.05) than @entity10672 d 2. A positive RAST to @entity10672 d 2 was obtained for 88.2% of the subjects, while only 35.2% displayed a positive RAST to @entity10672 d 2.6Cys. CONCLUSION: This study demonstrates that @entity10672 d 2.6Cys is less able to evoke IgE-mediated reactions and cellular responses, as measured both in skin and in serum, than @entity10672 d 2. In the future this hypoallergenic derivative may be a promising candidate molecule for immunotherapy of L. destructor- @entity56 @entity1 .

A hypoallergenic derivative of the major allergen of the dust mite Lepidoglyphus destructor, XXXX d 2.6 @entity2569 , induces less IgE reactivity and cellular response in the skin than recombinant @entity1243 d 2.

@entity10672 :: ('25608(Tax:10116)', 'Gene') :: ['rLep'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity2569 :: ('CHEBI:17561', 'Chemical') :: ['Cys'] @entity1243 :: ('3952', 'Gene') :: ['Lep'] @entity1711 :: ('MESH:D004801', 'Chemical') :: ['eosin'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['Dermal cell infiltrates'] @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic'] @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine'] @entity4896 :: ('909', 'Gene') :: ['CD1a']
@entity1243 :: (3952,Gene) :: ['Lep']
